PTCT Ptc Therapeutics Inc

Price (delayed)

$47.45

Market cap

$3.34B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.64

Enterprise value

$3.55B

Sector: Healthcare
Industry: Biotechnology

Highlights

Ptc Therapeutics's revenue has increased by 24% YoY and by 6% from the previous quarter
PTCT's gross profit is up by 23% YoY and by 6% QoQ
The EPS has dropped by 56% year-on-year but it is up by 3.5% since the previous quarter
The quick ratio rose by 34% year-on-year but it has declined by 10% since the previous quarter
The net income has plunged by 74% YoY
The company's debt rose by 28% YoY

Key stats

What are the main financial stats of PTCT
Market
Shares outstanding
70.32M
Market cap
$3.34B
Enterprise value
$3.55B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.72
Price to sales (P/S)
8.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.32
Earnings
Revenue
$380.77M
EBIT
-$346.58M
EBITDA
-$255.62M
Free cash flow
-$211.91M
Per share
EPS
-$6.64
Free cash flow per share
-$3.21
Book value per share
$7.06
Revenue per share
$5.77
TBVPS
$21.36
Balance sheet
Total assets
$2.21B
Total liabilities
$1.73B
Debt
$420.44M
Equity
$481.98M
Working capital
$954.41M
Liquidity
Debt to equity
0.87
Current ratio
4.44
Quick ratio
4.23
Net debt/EBITDA
-0.83
Margins
EBITDA margin
-67.1%
Gross margin
95%
Net margin
-115.1%
Operating margin
-107.3%
Efficiency
Return on assets
-23.6%
Return on equity
-83.7%
Return on invested capital
-36%
Return on capital employed
-17.9%
Return on sales
-91%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
-2.35%
1 week
0.68%
1 month
-15.54%
1 year
-4.68%
YTD
-22.25%
QTD
0.21%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$380.77M
Gross profit
$361.82M
Operating income
-$408.49M
Net income
-$438.16M
Gross margin
95%
Net margin
-115.1%
The company's operating income has shrunk by 112% YoY and by 8% QoQ
The net income has plunged by 74% YoY
PTCT's operating margin has dropped by 71% year-on-year
The company's net margin fell by 40% YoY but it rose by 7% QoQ

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
6.72
P/S
8.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.32
The EPS has dropped by 56% year-on-year but it is up by 3.5% since the previous quarter
PTCT's P/B is 40% above its 5-year quarterly average of 4.9 and 8% above its last 4 quarters average of 6.4
Ptc Therapeutics's equity has decreased by 19% YoY and by 6% QoQ
Ptc Therapeutics's revenue has increased by 24% YoY and by 6% from the previous quarter
The price to sales (P/S) is 22% higher than the 5-year quarterly average of 6.9 but 13% lower than the last 4 quarters average of 9.7

Efficiency

How efficient is Ptc Therapeutics business performance
The return on equity has dropped by 88% year-on-year and by 4.6% since the previous quarter
Ptc Therapeutics's ROA has decreased by 37% YoY but it has increased by 9% from the previous quarter
The ROIC has grown by 30% YoY and by 24% from the previous quarter
The ROS is down by 23% year-on-year but it is up by 12% since the previous quarter

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 28% more than the total liabilities
PTCT's total liabilities has surged by 68% year-on-year and by 3.4% since the previous quarter
The total assets has grown by 36% YoY
The company's debt is 13% lower than its equity
PTCT's debt to equity has surged by 58% year-on-year and by 7% since the previous quarter
The company's debt rose by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.